Abou-Chebl Alex
Department of Neurology, University of Louisville School of Medicine, Louisville, Ky., USA.
Interv Neurol. 2013 Mar;1(2):100-8. doi: 10.1159/000346769.
Intra-arterial therapy (IAT) for acute ischemic stroke treatment is evolving. Whereas the efficacy of recanalization with traditional intra-arterial fibrinolysis is relatively poor, mechanically based recanalization with multimodal approaches, stenting and mechanical embolectomy is more effective. Until recently, this has not resulted in overwhelming clinical benefit and has not always equated with reperfusion. The reasons for this are not clearly known but may include inadequate patient selection, poor technique, low operator experience, direct injury from thrombolytics or devices, microvascular occlusions, complications of general anesthesia, or some other unknown factors. Intracerebral hemorrhage still complicates 2-11% of procedures. Large prospective and randomized clinical trials are needed to determine the safety and efficacy of IAT be it pharmacological therapy, embolectomy, stenting, or multimodal therapy. Comparative studies between the newer stent retriever devices and intravenous tissue plasminogen activators may also be needed especially for the 3- to 4.5-hour window.
用于急性缺血性卒中治疗的动脉内治疗(IAT)正在不断发展。传统动脉内溶栓再通的疗效相对较差,而基于机械的多模式再通方法、支架置入和机械取栓则更有效。直到最近,这并未带来压倒性的临床益处,也并不总是等同于再灌注。其原因尚不清楚,但可能包括患者选择不当、技术欠佳、术者经验不足、溶栓药物或器械造成的直接损伤、微血管闭塞、全身麻醉并发症或其他一些未知因素。脑出血在2%至11%的手术中仍会导致并发症。需要开展大型前瞻性随机临床试验来确定IAT(无论是药物治疗、取栓、支架置入还是多模式治疗)的安全性和有效性。可能还需要对新型支架取栓装置与静脉注射组织型纤溶酶原激活剂进行对比研究,尤其是在3至4.5小时的时间窗内。